Trulicity Cost in West Virginia 2026: Prices, Medicaid, and Savings Options

What Does Trulicity Actually Cost in West Virginia in 2026?

The cash-pay price for Trulicity at West Virginia retail pharmacies sits at approximately $931 per month in 2026, matching Eli Lilly's current manufacturer list price. That figure covers a four-pen supply (four once-weekly doses). No meaningful regional discount applies at West Virginia chain pharmacies compared with the national list price, because Eli Lilly sets the wholesale acquisition cost centrally.

The $931 figure is the starting point before any coverage, savings card, or coupon is applied. Patients paying this amount out of pocket are leaving money on the table. Several structured programs can reduce that number substantially, and the sections below walk through each one.

Dulaglutide belongs to the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class. The FDA approved it in September 2014 under the brand name Trulicity for glycemic control in adults with type 2 diabetes [1]. The drug works by stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying, effects well-characterized across the AWARD clinical program [2]. A subsequent indication for cardiovascular risk reduction followed the REWIND trial, discussed in detail below.

GoodRx and similar discount aggregators occasionally list prices in the $850, $920 range at specific West Virginia ZIP codes, but these negotiated rates fluctuate weekly and require that patients forgo their insurance benefit for that fill. Pharmacists at WV retail chains including CVS, Walgreens, and Kroger can apply GoodRx coupons at the counter, though patients should confirm the final price before the claim is submitted.

Does West Virginia Medicaid Cover Trulicity?

West Virginia Medicaid does not cover Trulicity (dulaglutide) for standard fee-for-service or managed-care enrollees as of 2026. The state's preferred drug list (PDL) excludes dulaglutide without a non-preferred exception, and those exceptions are rarely granted given the availability of metformin and older sulfonylureas at near-zero cost [3].

WV Medicaid managed care organizations, including Aetna Better Health of West Virginia and The Health Plan, publish their own formularies. Neither lists dulaglutide as a preferred GLP-1 agent. Semaglutide (Ozempic) faces similar restrictions. Exenatide extended-release (Bydureon BCise) has appeared on some WV Medicaid PDLs as a non-preferred alternative requiring prior authorization, but coverage is not guaranteed.

Patients enrolled in West Virginia's Children's Health Insurance Program (CHIP) face the same formulary restrictions. Adults with dual Medicare-Medicaid eligibility may access dulaglutide through their Medicare Part D plan if the specific plan's formulary includes it, though many Part D plans in WV place dulaglutide on tier 3 or tier 4, generating a $70, $150 co-pay per fill even after low-income subsidy (LIS) adjustments [4].

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended as part of the glucose-lowering regimen" [5]. West Virginia's Medicaid coverage policy creates a direct conflict with this guideline for the state's low-income population, where cardiovascular disease rates are among the highest in the nation.

WV has the second-highest age-adjusted cardiovascular mortality rate in the United States, at 224.6 deaths per 100,000 population, according to the CDC [6]. That context matters when evaluating formulary exclusions for a drug class with demonstrated cardioprotective data.

The REWIND Trial: Why Cardiovascular Risk Matters for WV Patients

The REWIND trial (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) enrolled 9,901 adults with type 2 diabetes across 24 countries and followed them for a median of 5.4 years [7]. Participants received dulaglutide 1.5 mg once weekly or placebo on top of standard care.

The primary endpoint, a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (3-point MACE), occurred in 12.0% of dulaglutide-treated patients versus 13.4% of placebo patients. That translates to a hazard ratio of 0.88 (95% CI 0.79, 0.98, P<0.026), a statistically significant 12% relative risk reduction [7]. Nonfatal stroke showed a particularly strong signal: hazard ratio 0.76 (95% CI 0.61, 0.95).

Critically, 46% of REWIND participants had no prior cardiovascular event at baseline, making REWIND the only GLP-1 RA cardiovascular outcomes trial to show benefit in a predominantly primary-prevention population [7]. West Virginia's high burden of hypertension, obesity, and smoking creates a population profile that overlaps substantially with the REWIND primary-prevention subgroup.

These findings led the FDA to update the Trulicity label to include a cardiovascular risk reduction indication for adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1]. For West Virginia clinicians managing this population, the REWIND data provide a direct evidence base for prioritizing dulaglutide when cost barriers can be overcome.

Which Commercial Insurance Plans Cover Trulicity in West Virginia?

Most major commercial insurers operating in West Virginia cover Trulicity, but nearly all require prior authorization (PA). The standard PA criteria across BlueCross BlueShield of West Virginia, United HealthCare, and Aetna commercial plans demand documentation of an HbA1c above 7.0%, a trial of at least 90 days on metformin (unless contraindicated), and a documented reason for preferring a GLP-1 RA over a DPP-4 inhibitor [8].

Tier placement determines co-pay after PA approval. Typical tier 3 placement generates a $60, $100 monthly co-pay. Some plans, including certain ACA marketplace silver plans offered through the WV exchange, place dulaglutide on tier 4 specialty, with co-insurance ranging from 25 to 40% of the allowed amount. On a $931 list price, 30% co-insurance equals $279 per month before any manufacturer savings card is applied.

The Inflation Reduction Act capped Medicare Part D out-of-pocket drug spending at $2,000 annually beginning in 2025, which provides meaningful protection for Medicare beneficiaries in WV who have dulaglutide covered on their Part D plan [9]. For a patient paying $150 per fill, the $2,000 cap is reached by mid-year, after which cost-sharing drops to zero.

Employers self-insuring under ERISA plans set their own formularies and are not bound by ACA metal-tier requirements. West Virginia has a relatively high concentration of small employers, and self-insured plans at that scale are less common. Most small-group WV employers use fully insured plans subject to ACA rules, meaning the standard tier structures above apply.

How Does the Eli Lilly Savings Card Work in West Virginia?

Eli Lilly offers two separate programs, and confusing them is one of the most common and costly mistakes WV patients make. The Trulicity Savings Card (also called the Lilly Cares commercial coupon) reduces monthly cost to as low as $25 for commercially insured patients. The Lilly Insulin Value Program is a separate offering for uninsured or underinsured patients [10].

For the $25 savings card, eligibility requirements are specific. The patient must have commercial insurance that covers Trulicity (even partially). Medicare, Medicaid, TRICARE, and other government-funded plans are explicitly excluded. West Virginia Medicaid enrollees do not qualify. The savings card is accepted at most West Virginia retail pharmacies including Rite Aid, CVS, and Walgreens locations.

The maximum annual benefit on the commercial savings card is $3,600, or roughly $300 per month in manufacturer subsidy. If a patient's out-of-pocket after insurance exceeds $325 per fill, the card covers the excess up to that cap. Patients should check Lilly's enrollment portal annually because the terms reset each calendar year [10].

For uninsured WV patients, the Lilly Cares Foundation Patient Assistance Program provides Trulicity at no cost to qualifying individuals with household income at or below 400% of the federal poverty level. A single adult earning under approximately $60 to 240 in 2026 may qualify. The application requires proof of income, a prescription, and confirmation of no qualifying insurance coverage [10]. Processing typically takes two to four weeks.

The HealthRX Cost Navigation Framework for West Virginia Trulicity patients runs through four sequential steps: (1) Check whether your commercial plan covers dulaglutide and submit a PA. (2) If PA is approved, apply the Lilly savings card to reduce your co-pay to $25. (3) If you are uninsured and below 400% FPL, apply to the Lilly Cares Foundation. (4) If none of the above applies and your prescriber has documented medical necessity, ask about a licensed 503A compounding pharmacy. Each step has a defined off-ramp before spending $931 cash.

Is Compounded Dulaglutide Legal in West Virginia?

Compounded dulaglutide is available through licensed 503A pharmacies operating in West Virginia, but the legal and safety picture deserves careful attention before a patient pursues this route.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare drugs for individual patients based on a valid prescription [11]. A licensed 503A pharmacy in West Virginia may compound dulaglutide if a licensed prescriber issues a patient-specific prescription and the pharmacy uses ingredients from an FDA-registered outsourcing facility or an FDA-approved bulk substance. State law in West Virginia requires that compounding pharmacies hold an active license from the West Virginia Board of Pharmacy, and the pharmacy must comply with United States Pharmacopeia (USP) Chapter 795 standards for non-sterile preparations and USP Chapter 797 for sterile injectable compounds [12].

The FDA has not approved any compounded version of dulaglutide. Trulicity's pen delivery system, which uses a proprietary formulation, cannot be replicated exactly in a compounding pharmacy setting. Compounded dulaglutide may differ in concentration, excipients, and sterility assurance from the branded product. The FDA's Center for Drug Evaluation and Research has stated that the GLP-1 RA drug class does not appear on the FDA drug shortage list as of mid-2025, which limits but does not eliminate the legal basis for compounding [11].

Patients should verify the following before using a 503A compounding pharmacy for dulaglutide in West Virginia: active WV Board of Pharmacy license, USP 797-compliant sterile compounding facility, third-party certificate of analysis for each batch, and a clear written prescription from a licensed WV prescriber. The WV Board of Pharmacy maintains a public license verification database at wvbop.com [12].

Price for compounded dulaglutide at licensed 503A pharmacies serving West Virginia patients varies from under $100 to $250 per month depending on dose and volume. That represents a substantial reduction from the $931 retail list price, though insurance reimbursement for compounded versions is not available.

Can a West Virginia Resident Get Trulicity via Telehealth?

Telehealth prescribing of Trulicity is legal in West Virginia. The state adopted permanent telehealth prescribing rules following the COVID-19 public health emergency, and West Virginia Code §30-3-13a permits a licensed WV physician to establish a valid patient-physician relationship and prescribe Schedule III, V controlled substances and non-controlled medications via synchronous audio-visual telehealth without a prior in-person visit [13].

Dulaglutide is not a controlled substance, so the prescribing requirements are less restrictive than for, say, testosterone or stimulants. A WV-licensed provider conducting a telehealth visit must review the patient's medical history, confirm a type 2 diabetes diagnosis (or elevated cardiovascular risk), assess contraindications including personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, and document clinical justification for the chosen agent [1].

HealthRX providers licensed in West Virginia can prescribe dulaglutide after a synchronous video consultation that typically runs 20 to 30 minutes. A fasting glucose, HbA1c, and basic metabolic panel within the prior 12 months are the minimum lab requirements. Patients in rural WV counties, where endocrinologists are sparse, benefit most from this pathway. Forty-four of West Virginia's 55 counties are designated as Health Professional Shortage Areas for primary care [14].

The prescription can be sent to any retail pharmacy in the patient's county or to a licensed 503A compounding pharmacy if the prescriber determines compounded dulaglutide is clinically appropriate.

Practical Dosing and Administration for WV Patients

Trulicity is injected subcutaneously once weekly, on the same day each week, into the abdomen, thigh, or upper arm. The starting dose is 0.75 mg weekly. After four weeks, the dose may be escalated to 1.5 mg based on glycemic response and tolerability [1].

Two additional doses, 3.0 mg and 4.5 mg, received FDA approval in 2020 for patients requiring further glycemic control beyond what 1.5 mg provides [1]. The dose escalation schedule for these higher tiers is: at least four weeks at 1.5 mg before moving to 3.0 mg, then at least four weeks at 3.0 mg before moving to 4.5 mg. A 2022 analysis published in Diabetes Care demonstrated that patients escalated to 3.0 mg and 4.5 mg achieved additional HbA1c reductions of 0.5% and 0.7% respectively compared with remaining at 1.5 mg (P<0.001 for both) [15].

Nausea is the most frequently reported adverse effect, occurring in approximately 12 to 21% of patients in clinical trials, depending on dose [2]. Starting at 0.75 mg and escalating slowly reduces early gastrointestinal side effects. Trulicity carries an FDA boxed warning for risk of thyroid C-cell tumors based on rodent data; the clinical relevance in humans is unknown, but the drug is contraindicated in patients with personal or family history of medullary thyroid carcinoma [1].

Storage requires refrigeration at 36, 46°F (2, 8°C). Each pen can remain at room temperature (no more than 77°F) for up to 14 days. West Virginia summers routinely exceed 90°F, so patients traveling or without reliable refrigeration should plan accordingly and not leave pens in parked vehicles.

West Virginia-Specific Savings Programs Beyond Lilly Cares

West Virginia does not operate a state-funded drug assistance program specifically for GLP-1 receptor agonists. The state's Senior Rx and Bene55 programs, administered through the WV Bureau of Senior Services, provide drug cost assistance for Medicare Part D premiums and some out-of-pocket drug costs for residents aged 55 and older who meet income thresholds [16]. These programs do not cover the drug cost directly but reduce the insurance premium burden, freeing cash that may otherwise go toward premiums.

The NeedyMeds database lists several national charitable programs that accept WV residents and cover brand-name medications including GLP-1 agents. The Partnership for Prescription Assistance (PPA), administered through PPARX.org, connects patients with manufacturer and charitable programs and may identify coverage options that a retail pharmacist would not flag [17].

For patients with private insurance who exhaust the Lilly savings card annual cap, a short-term pharmacy discount card from Cost Plus Drugs (Mark Cuban's Cost Plus Drug Company) does not currently carry dulaglutide in its formulary, as compounded and branded GLP-1 agents are not part of that platform's model. GoodRx Gold membership at $9.99 per month provides the largest single-point discount at WV retail pharmacies, bringing the cash price to approximately $880, $910 at select locations. That is still a high number and underscores why insurance coverage or the Lilly savings card pathway is the superior first step.

Comparing Dulaglutide to Other GLP-1 Options on WV Formularies

Patients for whom cost is the primary barrier should know how dulaglutide compares to other GLP-1 RAs available in West Virginia. Semaglutide (Ozempic, 0.5 to 2.0 mg weekly) carries a similar list price of approximately $935/month and faces the same WV Medicaid exclusions [18]. Exenatide extended-release (Bydureon BCise) has appeared on some WV Medicaid PDLs as a non-preferred alternative.

Oral semaglutide (Rybelsus, 3 to 14 mg daily) is sometimes placed on a lower tier than injectable semaglutide on commercial plans, which may generate a lower co-pay for some WV patients. The PIONEER 6 trial (N=3,183) found oral semaglutide met non-inferiority for cardiovascular safety against placebo (HR 0.79 to 95% CI 0.57, 1.11), though the trial was not powered to demonstrate superiority [19]. For patients with strong cardiovascular indications, injectable dulaglutide's REWIND data remain the more persuasive evidence set.

Liraglutide (Victoza, 1.2 to 1.8 mg daily) is injected daily rather than weekly and carries a list price of approximately $750/month, modestly lower. The LEADER trial (N=9,340) showed liraglutide reduced 3-point MACE by 13% (HR 0.87 to 95% CI 0.78, 0.97, P<0.001 for superiority) in patients with established cardiovascular disease or high risk [20]. Weekly dosing adherence is generally higher than daily dosing, which may favor dulaglutide for WV patients managing multiple conditions.

The American Association of Clinical Endocrinology (AACE) 2023 Comprehensive Type 2 Diabetes Management Algorithm states: "GLP-1 RAs with proven ASCVD benefit should be prioritized in patients with type 2 diabetes and ASCVD or high ASCVD risk regardless of HbA1c" [21]. West Virginia prescribers operating under that guideline face a practical challenge when the preferred agents are not covered by state Medicaid and carry $931 list prices.

What to Bring to Your Pharmacist or Telehealth Appointment

Before your first Trulicity fill at a West Virginia pharmacy, have these items ready: your current insurance card, the prescriber's prior authorization reference number (if PA was submitted), your household income documentation if applying to Lilly Cares, and a printed or digital copy of the Lilly savings card enrollment confirmation if you are commercially insured.

Ask the pharmacist specifically whether the claim is being submitted to your insurance as a pharmacy benefit (most common) or a medical benefit. Some infused or administered GLP-1 agents process under medical benefit Part B for Medicare patients, but Trulicity's self-administered pen format means it runs through Part D pharmacy benefit for Medicare patients. Getting this wrong delays the fill and misapplies any savings card benefit.

If your prescriber submitted a PA and it was denied, request a peer-to-peer review within 24 to 48 hours. WV law requires that managed care organizations complete expedited appeals within 72 hours when a prescriber certifies that the standard 30-day timeframe would seriously jeopardize the patient's health [22]. The REWIND cardiovascular data and your patient's documented ASCVD risk factors constitute a defensible clinical argument for expedited review.

For telehealth patients, the pharmacy fill can happen the same day the prescription is sent electronically to the pharmacy. Most WV telehealth platforms, including HealthRX, use SureScripts-connected e-prescribing, so transmission from provider to WV pharmacy is near-instantaneous. Patients in rural counties who prefer mail-order should confirm their Part D or commercial plan's mail-order pharmacy is in-network; out-of-network mail-order fills often carry the same cost as retail even if the plan nominally covers mail order.